4.2 Article

TRAF-Interacting Protein with a Forkhead-Associated Domain B (TIFAB) Is a Negative Regulator of the TRAF6-Induced Cellular Functions

期刊

JOURNAL OF BIOCHEMISTRY
卷 146, 期 3, 页码 375-381

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jb/mvp080

关键词

cell cycle; forkhead-associated domain; NF-kappa B; TIFA; TRAF

资金

  1. Grant-in-Aid for Scientific Research on Priority Area [17014017, 18799010]
  2. Ministry of Education, Culture, Sports, Science and Technology of the Japanese government
  3. Grants-in-Aid for Scientific Research [17014017, 18799010] Funding Source: KAKEN

向作者/读者索取更多资源

Tumour necrosis factor receptor-associated factor (TRAF)-interacting protein with a forkhead-associated domain (TIFA) activates TRAF6 to induce NF-kappa B activation. TIFA-related protein, TIFAB, is highly expressed in the spleen and inhibits TIFA-mediated TRAF6 activation. However, little is known about cell types that express TIFAB and its function in those cells. Here, we show that TIFAB is mainly expressed in B cells rather than T cells in the spleen and that the expression level was much higher in dendritic cells (DCs) and macrophages than that in splenic lymphocytes. TIFAB expression was downregulated when B cells, DCs or macrophages were stimulated by TRAF6-mediated proliferative or maturation signals including those emanating from CD40, sIgM and TLRs. Furthermore, microinjection experiments using NIH3T3 cells revealed that TIFAB inhibited entry into the S phase of the cell cycle. Our results suggest that TIFAB could act as a negative regulator of the TRAF6-induced cellular function such as B cell proliferation and maturation of DCs and macrophages.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

Diagnosis of NTM active infection in lymphadenopathy patients with anti-interferon-gamma auto-antibody using inhibitory ELISA vs. indirect ELISA

Arnone Nithichanon, Ploenchan Chetchotisakd, Takayuki Matsumura, Yoshimasa Takahashi, Manabu Ato, Takuro Sakagami, Ganjana Lertmemongkolchai

SCIENTIFIC REPORTS (2020)

Article Cell Biology

Association of HLA-DRB1*09:01 with severe COVID-19

Alitzel Anzurez, Izumi Naka, Shoji Miki, Kaori Nakayama-Hosoya, Mariko Isshiki, Yusuke Watanabe, Midori Nakamura-Hoshi, Sayuri Seki, Takayuki Matsumura, Tomohiro Takano, Taishi Onodera, Yu Adachi, Saya Moriyama, Kazutaka Terahara, Natsuo Tachikawa, Yoshihiro Yoshimura, Hiroaki Sasaki, Hiroshi Horiuchi, Nobuyuki Miyata, Kazuhito Miyazaki, Michiko Koga, Kazuhiko Ikeuchi, Hiroyuki Nagai, Makoto Saito, Eisuke Adachi, Hiroshi Yotsuyanagi, Satoshi Kutsuna, Akira Kawashima, Yusuke Miyazato, Noriko Kinoshita, Chiyoko Kouno, Kensuke Tanaka, Yoshimasa Takahashi, Tadaki Suzuki, Tetsuro Matano, Jun Ohashi, Ai Kawana-Tachikawa

Summary: The study found a significant association between the HLA-DRB1*09:01 allele and severe COVID-19, with a higher risk compared to preexisting medical conditions such as hypertension, diabetes, and cardiovascular diseases. These results suggest a potential role for HLA in predisposing individuals to severe COVID-19.
Article Immunology

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants

Saya Moriyama, Yu Adachi, Takashi Sato, Keisuke Tonouchi, Lin Sun, Shuetsu Fukushi, Souichi Yamada, Hitomi Kinoshita, Kiyoko Nojima, Takayuki Kanno, Minoru Tobiume, Keita Ishijima, Yudai Kuroda, Eun-Sil Park, Taishi Onodera, Takayuki Matsumura, Tomohiro Takano, Kazutaka Terahara, Masanori Isogawa, Ayae Nishiyama, Ai Kawana-Tachikawa, Masaharu Shinkai, Natsuo Tachikawa, Shigeki Nakamura, Takahiro Okai, Kazu Okuma, Tetsuro Matano, Tsuguto Fujimoto, Ken Maeda, Makoto Ohnishi, Takaji Wakita, Tadaki Suzuki, Yoshimasa Takahashi

Summary: Antibody titers against SARS-CoV-2 decrease over time, but the neutralizing potency against the original virus and variants actually improves with time. Late convalescent antibodies show increased neutralization potency against variants, suggesting that antibody response maturation enhances cross-neutralizing ability against circulating variants. This indicates that declining antibody titers may not necessarily mean declining protection.

IMMUNITY (2021)

Article Multidisciplinary Sciences

On-admission SARS-CoV-2 RNAemia as a single potent predictive marker of critical condition development and mortality in COVID-19

Shoji Miki, Hiroaki Sasaki, Hiroshi Horiuchi, Nobuyuki Miyata, Yukihiro Yoshimura, Kazuhito Miyazaki, Takayuki Matsumura, Yoshimasa Takahashi, Tadaki Suzuki, Tetsuro Matano, Ai Kawana-Tachikawa, Natsuo Tachikawa

Summary: This study demonstrates that SARS-CoV-2 RNAemia is a potent predictive marker of COVID-19 critical condition and mortality, with an adjusted OR for critical condition as high as 125.71.

PLOS ONE (2021)

Article Immunology

Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients

Xiuyuan Lu, Yuki Hosono, Masamichi Nagae, Shigenari Ishizuka, Eri Ishikawa, Daisuke Motooka, Yuki Ozaki, Nicolas Sax, Yuichi Maeda, Yasuhiro Kato, Takayoshi Morita, Ryo Shinnakasu, Takeshi Inoue, Taishi Onodera, Takayuki Matsumura, Masaharu Shinkai, Takashi Sato, Shota Nakamura, Shunsuke Mori, Teru Kanda, Emi E. Nakayama, Tatsuo Shioda, Tomohiro Kurosaki, Kiyoshi Takeda, Atsushi Kumanogoh, Hisashi Arase, Hironori Nakagami, Kazuo Yamashita, Yoshimasa Takahashi, Sho Yamasaki

Summary: Through single-cell TCR and RNA sequencing, researchers identified public cTfh clonotypes expanded in recovered COVID-19 patients, determined their epitopes in the conserved regions of spike protein, and found that these epitopes may be valuable candidates for booster antigens to enhance adaptive immunity against the virus.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Immunology

SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine

Ryutaro Kotaki, Yu Adachi, Saya Moriyama, Taishi Onodera, Shuetsu Fukushi, Takaki Nagakura, Keisuke Tonouchi, Kazutaka Terahara, Lin Sun, Tomohiro Takano, Ayae Nishiyama, Masaharu Shinkai, Kunihiro Oba, Fukumi Nakamura-Uchiyama, Hidefumi Shimizu, Tadaki Suzuki, Takayuki Matsumura, Masanori Isogawa, Yoshimasa Takahashi

Summary: Multiple SARS-CoV-2 variants, particularly Beta and Omicron, have the potential to evade neutralizing antibodies, even in those who have received two doses of the BNT162b2 mRNA vaccine. However, boosting with a third vaccine dose or breakthrough infection can improve the overall breadth of neutralizing antibodies. This study longitudinally profiles the cellular composition of RBD-binding memory B cell subsets and their antibody binding and neutralizing activity after the second dose of mRNA vaccine. It finds that two doses of mRNA vaccine induce an expanded antibody breadth over time, while a subset of resting memory B cells show the ability to produce Beta and Omicron-neutralizing antibodies.

SCIENCE IMMUNOLOGY (2022)

Article Virology

Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir

Kanako Shinada, Takashi Sato, Saya Moriyama, Yu Adachi, Masahiro Shinoda, Shinichiro Ota, Miwa Morikawa, Masamichi Mineshita, Takayuki Matsumura, Yoshimasa Takahashi, Masaharu Shinkai

Summary: The use of favipiravir in the treatment of COVID-19 accelerates viral clearance, preserves the generation and persistence of neutralizing antibodies, and does not interfere with the maturation of neutralizing potency against both WT SARS-CoV-2 and its variants.

VIRUSES-BASEL (2022)

Article Multidisciplinary Sciences

SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype

Kazutaka Terahara, Takashi Sato, Yu Adachi, Keisuke Tonouchi, Taishi Onodera, Saya Moriyama, Lin Sun, Tomohiro Takano, Ayae Nishiyama, Ai Kawana-Tachikawa, Tetsuro Matano, Takayuki Matsumura, Masaharu Shinkai, Masanori Isogawa, Yoshimasa Takahashi

Summary: The determinants of memory T cell longevity following SARS-CoV-2 infection are still unknown. This study found that the half-lives of CD4(+) and CD8(+) T cells were longer than antibody titers. Th17-like subset of CD4(+) T cells showed the longest half-life, indicating its close association with T cell longevity. In contrast, Th2 and Tfh-like T cells were more closely correlated with antibody levels.

ISCIENCE (2022)

Article Multidisciplinary Sciences

Multimodal single-cell analyses of peripheral blood mononuclear cells of COVID-19 patients in Japan

Yukie Kashima, Taketoshi Mizutani, Kaori Nakayama-Hosoya, Saya Moriyama, Takayuki Matsumura, Yoshihiro Yoshimura, Hiroaki Sasaki, Hiroshi Horiuchi, Nobuyuki Miyata, Kazuhito Miyazaki, Natsuo Tachikawa, Yoshimasa Takahashi, Tadaki Suzuki, Sumio Sugano, Tetsuro Matano, Ai Kawana-Tachikawa, Yutaka Suzuki

Summary: Through the analysis of single-cell transcriptome and T cell receptor repertoire, differences in cell proportions and gene expression profiles were found between mild and severe cases of COVID-19, as well as among severe cases. In a severely infected elderly patient, characteristics such as depletion of naive T cells, low T cell receptor repertoire diversity, and aberrant hyperactivation of immune cell subsets were observed. This study provides valuable insights into the diversity of immune landscapes and responses.

SCIENTIFIC REPORTS (2023)

Article Immunology

Systemically inoculated adjuvants stimulate pDC-dependent IgA response in local site

Eita Sasaki, Hideki Asanuma, Haruka Momose, Keiko Furuhata, Takuo Mizukami, Takayuki Matsumura, Yoshimasa Takahashi, Isao Hamaguchi

Summary: The mechanisms of how non-mucosal inoculation of adjuvants stimulates the plasmacytoid dendritic cell (pDC)-dependent immunoglobulin (Ig)A response in the lungs are clarified in this study. The combination of systemic inoculation with type 1 interferon (IFN)-inducing adjuvants and intranasal antigen sensitization protects mice against influenza virus infection. These results provide insights into novel mucosal vaccine strategies using non-mucosal inoculated adjuvants.

MUCOSAL IMMUNOLOGY (2023)

Article Multidisciplinary Sciences

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain

Tomohiro Takano, Takashi Sato, Ryutaro Kotaki, Saya Moriyama, Shuetsu Fukushi, Masahiro Shinoda, Kiyomi Kabasawa, Nagashige Shimada, Mio Kousaka, Yu Adachi, Taishi Onodera, Kazutaka Terahara, Masanori Isogawa, Takayuki Matsumura, Masaharu Shinkai, Yoshimasa Takahashi

Summary: Takano et al. demonstrate that a heterologous booster using a SARS-CoV-2 recombinant spike protein vaccine induces a more sustained and broader anti-spike receptor-binding domain antibody response compared to a homologous booster using an mRNA vaccine. The study shows that the S-268019-b spike protein booster generates higher and longer-lasting IgG titers specific to the SARS-CoV-2 spike receptor-binding domain, with the ability to bind to antigenically distinct variants, while the BNT162b2 mRNA homologous booster has a weaker effect. Additionally, the S-268019-b booster enhances the production of RBD-angiotensin-converting enzyme 2 (ACE2) binding inhibitory antibodies, resulting in increased neutralizing activities against Omicron BA.1 and BA.5 variants.

NATURE COMMUNICATIONS (2023)

Article Multidisciplinary Sciences

CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes

Taishi Onodera, Nicolas Sax, Takashi Sato, Yu Adachi, Ryutaro Kotaki, Takeshi Inoue, Ryo Shinnakasu, Takayuki Nakagawa, Shuetsu Fukushi, Tommy Terooatea, Mai Yoshikawa, Keisuke Tonouchi, Takaki Nagakura, Saya Moriyama, Takayuki Matsumura, Masanori Isogawa, Kazutaka Terahara, Tomohiro Takano, Lin Sun, Ayae Nishiyama, Shinnya Omoto, Masaharu Shinkai, Tomohiro Kurosaki, Kazuo Yamashita, Yoshimasa Takahashi

Summary: By analyzing single Bmem cells and assessing antibody function, we have identified the characteristics of Bmem cells that carry potent neutralizing antibodies in COVID-19 convalescent individuals. These neutralizing antibodies are marked by elevated CD62L expression, distinct epitope preference, and usage of convergent VH genes, which contribute to their neutralizing activities. Despite equivalent receptor binding, there is a correlation between neutralizing antibody titers and the CD62L+ subset. Moreover, the dynamics of the CD62L+ subset differ among patients with varying COVID-19 severities. Our Bmem cell profiling reveals the unique phenotype of the subset harboring potent neutralizing BCRs and enhances our understanding of humoral protection.

SCIENCE ADVANCES (2023)

Article Cell Biology

Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine

Tomohiro Takano, Miwa Morikawa, Yu Adachi, Kiyomi Kabasawa, Nicolas Sax, Saya Moriyama, Lin Sun, Masanori Isogawa, Ayae Nishiyama, Taishi Onodera, Kazutaka Terahara, Keisuke Tonouchi, Masashi Nishimura, Kentaro Tomii, Kazuo Yamashita, Takayuki Matsumura, Masaharu Shinkai, Yoshimasa Takahashi

Summary: By applying high-dimensional immune profiling, the study identified vaccine-induced immune dynamics that correlate with neutralizing antibody levels, adverse event severity, or both. Natural killer cells, dendritic cell subsets, and NKT-like cells were found to play important roles in these immune dynamics.

CELL REPORTS MEDICINE (2022)

Article Parasitology

Evaluation of the stability of Yamakagashi (Rhabdophis tigrinus) Equine Antivenom after 20 years storage

K. Morokuma, T. Matsumura, A. Yamamoto, A. Sakai, T. Hifumi, M. Ato, M. Takahashi

Summary: The equine Yamakagashi antivenom manufactured in 2000 as an unapproved drug showed strong neutralizing ability against the venom's activity and remained stable and effective after 20 years, passing quality control tests and maintaining potency and safety within standard values.

TROPICAL BIOMEDICINE (2021)

Article Immunology

Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in Japan

Tomohiro Takano, Takayuki Matsumura, Yu Adachi, Kazutaka Terahara, Saya Moriyama, Taishi Onodera, Ayae Nishiyama, Ai Kawana-Tachikawa, Shoji Miki, Kaori Hosoya-Nakayama, Midori Nakamura-Hoshi, Sayuri Seki, Natsuo Tachikawa, Yukihiro Yoshimura, Nobuyuki Miyata, Hiroshi Horiuchi, Hiroaki Sasaki, Kazuhito Miyazaki, Noriko Kinoshita, Tsutomu Sudo, Yutaro Akiyama, Rubuna Sato, Tadaki Suzuki, Tetsuro Matano, Yoshimasa Takahashi

Summary: An expanded myeloid cell compartment is a key feature of severe COVID-19, with polymorphonuclear (PMN)-MDSCs selectively expanding in survivors of severe cases in Japan, positively correlating with IL-8 levels. This transient expansion of PMN-MDSC subset could serve as a predictor of prognosis in severe COVID-19 cases.

INTERNATIONAL IMMUNOLOGY (2021)

暂无数据